Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jun 4:12:1481-1491.
doi: 10.2147/IDR.S180908. eCollection 2019.

Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review

Guy El Helou  1   2 , Raymund R Razonable  1   2
Affiliations
Review

Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review

Guy El Helou et al. Infect Drug Resist. .

Abstract

Cytomegalovirus (CMV) is a leading opportunistic infection in immune compromised patients, including allogeneic hematopoietic stem cell (HSCT) or solid organ transplant (SOT) recipients, where primary infection or reactivation is associated with increased morbidity and mortality. Antiviral drugs are the mainstay for the prevention of CMV infection and disease, most commonly with valganciclovir. However, valganciclovir use is often associated with adverse drug reactions, most notably leukopenia and neutropenia, and its widespread use has led to emergence of antiviral resistance. Foscarnet and cidofovir, however, are associated with nephrotoxicity. Letermovir, a novel CMV viral terminase inhibitor drug, was recently approved for CMV prophylaxis in allogeneic HSCT recipients. It has a favorable pharmacokinetic and tolerability profile. The aim of this paper is to review the evidence supporting the use of letermovir in allogeneic HSCT recipients, and how the drug impacts our contemporary clinical practice. In addition, we discuss the ongoing clinical trial of letermovir for the prevention of CMV in SOT recipients. The use of letermovir for treatment of CMV infection and disease is not yet approved. However, because of a unique mechanism of activity, we provide our perspective on the potential role of letermovir in the treatment of ganciclovir-resistant CMV infection and disease. Furthermore, drug-resistant CMV has emerged during use of letermovir for prophylaxis and treatment. Caution is advised on its use in order to preserve its therapeutic lifespan.

Keywords: UL56; UL97; cytomegalovirus; letermovir; transplantation; valganciclovir.

PubMed Disclaimer

Conflict of interest statement

Raymund Razonable reports grants from Roche, personal fees from Merck, personal fees from Novartis, outside the submitted work. The authors report no other conflicts of interest in this work.

References

    1. Gandhi MK, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis. 2004;4(12):725–738. doi: 10.1016/S1473-3099(04)01202-2 - DOI - PubMed
    1. Crough T, Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev. 2009;22(1):76–98. doi: 10.1128/CMR.00034-08 - DOI - PMC - PubMed
    1. Cope AV, Sabin C, Burroughs A, Rolles K, Griffiths PD, Emery VC. Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation. J Infect Dis. 1997;176(6):1484–1490. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9395358. - PubMed
    1. Koval CE. Prevention and treatment of cytomegalovirus infections in solid organ transplant recipients. Infect Dis Clin North Am. 2018;32(3):581–597. doi: 10.1016/j.idc.2018.04.008 - DOI - PubMed
    1. Timpone JG, Yimen M, Cox S, et al. Resistant cytomegalovirus in intestinal and multivisceral transplant recipients. Transpl Infect Dis. 2016;18(2):202–209. doi: 10.1111/tid.12507 - DOI - PubMed